Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Shares Issued (2016 - 2025)

Tg Therapeutics (TGTX) has 8 years of Shares Issued data on record, last reported at $1.1 million in Q4 2025.

  • For Q4 2025, Shares Issued rose 85.61% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $1.5 million, up 65.32%, while the annual FY2025 figure was $1.5 million, 65.32% up from the prior year.
  • Shares Issued reached $1.1 million in Q4 2025 per TGTX's latest filing, up from $432000.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $45.9 million in Q2 2023 and bottomed at -$44.8 million in Q4 2023.
  • Average Shares Issued over 5 years is $343222.2, with a median of $131500.0 recorded in 2021.
  • Peak YoY movement for Shares Issued: plummeted 620.0% in 2022, then skyrocketed 33927.41% in 2023.
  • A 5-year view of Shares Issued shows it stood at $2.0 million in 2021, then tumbled by 112.98% to -$260000.0 in 2022, then crashed by 17116.54% to -$44.8 million in 2023, then surged by 101.27% to $570000.0 in 2024, then soared by 85.61% to $1.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were $1.1 million in Q4 2025, $432000.0 in Q2 2025, and $21000.0 in Q1 2025.